Rein Therapeutics Inc.
RNTX
$1.76
-$0.15-7.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -458.40% | -220.03% | -400.39% | -48.84% | -61.40% |
| Total Depreciation and Amortization | -100.00% | -100.00% | -66.67% | 37.21% | 20.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8,188.62% | 173.12% | 31.45% | -50.66% | 48.84% |
| Change in Net Operating Assets | 72.86% | 13,918.18% | 114.03% | 813.10% | -1,624.27% |
| Cash from Operations | 53.69% | -132.87% | -169.22% | -13.09% | -135.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | -- | -- | -- | -- | -102.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.99% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 98.41% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -191.76% | -288.43% | 83.41% | -303.59% | 1,377.18% |